Markets
Alerts
F&O
MF
Reports
Screeners
Subscribe
Superstars
Portfolio
Watchlist
Insider Trades
Results
Data Downloader
Events Calendar
What's New
Explore
FAQs
Widgets
More
Search stocks
IND
USA
IND
IND
×
Close
IND
USA
Stocks
Futures & Options
Mutual Funds
News
Fundamentals
Reports
Corporate Actions
Alerts
Shareholding
Stocks
Kilitch Drugs(I) Ltd.
Swot
Kilitch Drugs(I) Ltd. SWOT Analysis: Strengths, Weakness, Opportunity, and Threats
Kilitch Drugs(I) Ltd. has 28 Strengths, 4 Weaknesses, 1 Opportunities and 0 Threats. The SWOT product gives you a quick x-ray of a stock's outlook and potential
Add SWOT widget to your site/app
Strengths
(28)
Weakness
(4)
Opportunity
(1)
Threats
(0)
Others
(2)
Positive Breakout First Resistance ( LTP > R1)
Companies with current TTM PE Ratio less than 3 Year, 5 Year and 10 Year PE
Strong Momentum: Price above short, medium and long term moving averages
Consistent Highest Return Stocks over Five Years - Nifty500
Mid-range Performer (DVM)
Relative Outperformance versus Industry over 1 Month
Company with high TTM EPS Growth
Annual Profit Growth higher than Sector Profit Growth
PEG lower than Industry PEG
Stocks gaining versus previous close, open price and RSI
High Momentum Scores (Technical Scores greater than 50)
Relative Outperformance versus Industry over 1 Week
Relative Outperformance versus Industry over 1 Month
Overbought by Money Flow Index (MFI)
Effectively using its capital to generate profit - RoCE improving in last 2 years
Effectively using Shareholders fund - Return on equity (ROE) improving since last 2 year
Efficient in managing Assets to generate Profits - ROA improving since last 2 year
Growth in Quarterly Net Profit with increasing Profit Margin (YoY)
Company with Low Debt
Increasing Revenue every quarter for the past 2 quarters
Annual Net Profits improving for last 2 years
Book Value per share Improving for last 2 years
Company with Zero Promoter Pledge
Recent Results : Growth in Operating Profit with increase in operating margins (YoY)
RSI indicating price strength
MACD crossed above zero line previous end of day
Top Gainers
Stocks Outperforming their Industry Price Change in the Quarter
Companies with growing costs YoY for long term projects
Stocks with Expensive Valuations according to the Trendlyne Valuation Score
Poor cash generated from core business - Declining Cash Flow from Operations for last 2 years
Declining Net Cash Flow : Companies not able to generate net cash
Weekly Momentum Gainers
Average Bullish Trend - Stocks with Medium Trendlyne Momentum Score versus Benchmarks
Decline in Net Profit with falling Profit Margin (QoQ)
